Module

New Agents in Development for Hepatitis B

Source: Hepatitis Annual Update 2006

New Agents in Development for Hepatitis B

Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

Patrick Marcellin, MD

CME CREDIT INFORMATION

Release Date: 08/02/06

Expiration Date: 08/01/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

List the drugs in clinical development for the treatment of hepatitis B, and their potential role in treatment
Recount the latest clinical trial data on new agents for the treatment of chronic hepatitis B
Identify drugs in earlier stages of development
Define strategies for developing new classes of drugs

Topics covered include:

Introduction
Nucleos(t)ide Analogues in Development: Telbivudine
Nucleos(t)ide Analogues in Development: Emtricitabine
Nucleos(t)ide Analogues in Development: Clevudine
Nucleos(t)ide Analogues in Development: Tenofovir
Evaluation of Peginterferon Alfa-2b for Treatment of Chronic Hepatitis B
Antivirals in Early Clinical Development or Preclinical Study: Nucleos(t)ide Inhibitors
Antivirals in Early Clinical Development or Preclinical Study: Small Molecule Antivirals
Future Directions and Conclusions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.